title: Paraneoplastic pemphigus associated with systemic mastocytosis.
authors: Department of Haematology, Royal Free Hospital, London, UK.
authors: Lydia R J
authors: LR
authors: Eccersley
authors: A Victor
authors: AV
authors: Hoffbrand
authors: Malcolm H A
authors: MH
authors: Rustin
authors: Christopher J
authors: CJ
authors: McNamara
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D017338:Cladribine / Q000627:therapeutic use; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008099:Liver / Q000473:pathology*; D008297:Male; D034721:Mastocytosis, Systemic / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000209:etiology / Q000473:pathology*; D010392:Pemphigus / Q000209:etiology / Q000473:pathology*; D015649:Pentostatin / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D000069283:Rituximab; D017211:Treatment Failure; D014582:Urticaria Pigmentosa / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D011743:Pyrimidines; D015649:Pentostatin; D017338:Cladribine; D000069283:Rituximab; C498826:nilotinib; D011241:Prednisone